2-methoxy-3-phenylquinoxaline | 33507-89-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-methoxy-3-phenylquinoxaline
• CAS: 33507-89-0
• 化学式: C₁₅H₁₂N₂O
• 分子量: 236.273
• InChiKey: CCLWPFRCYQRUBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methoxy-3-phenylquinoxaline 以75%的产率得到
  参考文献：
  名称：

  IIJIMA CHIHOKO; MORIKAWA TEIKO; HAYASHI EISAKU, YAKUGAKU DZASSI. YAKUGAKU ZASSNI, J. PHARM. SOS JAR. , 1975, 95,+

  摘要：

  DOI：
• 作为产物：
  描述：

  甲醇 、 2-氯-3-苯基喹噁啉 在 sodium 作用下， 以95%的产率得到2-methoxy-3-phenylquinoxaline
  参考文献：
  名称：

  Functionalization by metalation of the benzene moiety of benzodiazines. Determination of structures by long-range 1H-15N correlation at natural abundance. Diazines XXV

  摘要：

  The first lithiation of the benzene moiety of various quinazolinones, quinoxalines, and phthalazines has been performed. The effects of kind and positions of various directing groups towards the regioselectivity of the metalation have been studied. Unambiguous structure determinations of quinoxaline derivatives have been carried out by applying NMR GHMBC H-1-N-15 sequence. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00202-1

文献信息

• MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20080008681A1

  公开（公告）日：2008-01-10

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20090005387A1

  公开（公告）日：2009-01-01

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US8809264B2
  申请人：——

  公开号：US8809264B2

  公开（公告）日：2014-08-19
• [EN] METHOD FOR PRODUCING COMPOSITE MATERIAL FOR ELECTRODE COMPRISING QUINOXALINE BASED POLYMER, SUCH MATERIAL, ELECTRODE AND BATTERY USING THE SAME<br/>[FR] PROCEDE DE PRODUCTION DE MATERIAU COMPOSITE POUR ELECTRODE COMPRENANT UN POLYMERE A BASE DE QUINOXALINE, MATERIAU, ELECTRODE ET BATTERIE CORRESPONDANTS
  申请人：SHOWA DENKO KK

  公开号：WO2002103825A1

  公开（公告）日：2002-12-27

  The present invention relates to a method for producing a polymer/conductive carbon composite electrode comprising dehydration condensation polymerization of a tetramine derivative and a tetracarbonyl compound in the presence of an electrically conductive carbon material. The synthetized polymer comprises quinoxaline structural units such as polyphenyl quinoxaline (PPQ) and serves as an active material having proton conductivity. The composite material for electrode obtained by the method has a large capacity of inserting/releasing a proton and excellent in durability. An electrode comprising the composite material and a secondary battery comprising the electrode is excellent in safety and reliability high-speed current characteristics, has a longer life and a larger gravimetric energy density (Wh/kg).
• [EN] QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS MACROCYCLIQUES QUINOXALINYLIQUES DES PROTÉASES À SÉRINE DU VIRUS DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2008002924A2

  公开（公告）日：2008-01-03

  [EN] The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
  [FR] La présente invention concerne des composés, dont des composés de formule (I), ou un sel, ester ou promédicament acceptable du point de vue pharmaceutique de ceux-ci, lesquels inhibent l'activité des protéases à sérine, en particulier l'activité de la protéase NS3-NS4A du virus de l'hépatite C (VHC). En conséquence, les composés de la présente invention interfèrent avec le cycle biologique du virus de l'hépatite C et sont également utiles en tant qu'agents antiviraux. La présente invention concerne en outre des compositions pharmaceutiques comprenant les composés susmentionnés pour l'administration à un sujet souffrant d'une infection à VHC. L'invention concerne également des procédés de traitement d'une infection à VHC chez un sujet en administrant une composition pharmaceutique comprenant les composés de la présente invention.

表征谱图